EID, Michal, Paraskevi KAROUSI, Lumír KUNOVSKÝ, Štěpán TUČEK, Dagmar BRANČÍKOVÁ, Zdeněk KALA, Ondřej SLABÝ, Jiří MAYER, Christos K. KONTOS and Jan TRNA. The Role of Circulating MicroRNAs in Patients with Early-Stage Pancreatic Adenocarcinoma. Biomedicines. Basel: MDPI, 2021, vol. 9, No 10, p. 1-17. ISSN 2227-9059. Available from: https://dx.doi.org/10.3390/biomedicines9101468.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name The Role of Circulating MicroRNAs in Patients with Early-Stage Pancreatic Adenocarcinoma
Authors EID, Michal (203 Czech Republic, belonging to the institution), Paraskevi KAROUSI, Lumír KUNOVSKÝ (203 Czech Republic, belonging to the institution), Štěpán TUČEK (203 Czech Republic, belonging to the institution), Dagmar BRANČÍKOVÁ (203 Czech Republic, belonging to the institution), Zdeněk KALA (203 Czech Republic, belonging to the institution), Ondřej SLABÝ (203 Czech Republic, belonging to the institution), Jiří MAYER (203 Czech Republic, belonging to the institution), Christos K. KONTOS (guarantor) and Jan TRNA (203 Czech Republic, belonging to the institution).
Edition Biomedicines, Basel, MDPI, 2021, 2227-9059.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 10608 Biochemistry and molecular biology
Country of publisher Switzerland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 4.757
RIV identification code RIV/00216224:14110/21:00122646
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.3390/biomedicines9101468
UT WoS 000716958200001
Keywords in English pancreatic cancer; early stage; microRNA; diagnosis; prognosis; chemoresistance
Tags 14110212, 14110213, 14110223, 14110513, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 7/12/2021 13:36.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is increasing in incidence and is still associated with a high rate of mortality. Only a minority of patients are diagnosed in the early stage. Radical surgery is the only potential curative procedure. However, radicality is reached in 20% of patients operated on. Despite the multidisciplinary approach in resectable tumors, early tumor recurrences are common. Options on how to select optimal candidates for resection remain limited. Nevertheless, accumulating evidence shows an important role of circulating non-coding plasma and serum microRNAs (miRNAs), which physiologically regulate the function of a target protein. miRNAs also play a crucial role in carcinogenesis. In PDAC patients, the expression levels of certain miRNAs vary and may modulate the function of oncogenes or tumor suppressor genes. As they can be detected in a patient’s blood, they have the potential to become promising non-invasive diagnostic and prognostic biomarkers. Moreover, they may also serve as markers of chemoresistance. Thus, miRNAs could be useful for early and accurate diagnosis, prognostic stratification, and individual treatment planning. In this review, we summarize the latest findings on miRNAs in PDAC patients, focusing on their potential use in the early stage of the disease.
Links
MUNI/A/1595/2020, interní kód MUName: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit VIII (Acronym: VýDiTeHeMa VIII)
Investor: Masaryk University
PrintDisplayed: 10/7/2024 05:33